Results

Altered Plasma Lipid Profiles in HIV/ART
Lipoprotein compositions were determined in a large subset of HIV patients from the Heart Positive Study 15 (predominantly those who completed the 24-week trial). Subset plasma lipid profiles simulated those of the entire Heart Positive patient set ( Table I in the online-only Data Supplement). Treatment groups were 1, placebo; 2, diet and exercise (D&E); 3, fibrate+D&E; 4, niacin+D&E; 5, fibrate+niacin+D&E. In all 5 treatment groups, patient plasma lipid profiles at baseline satisfied the lipid criteria for metabolic syndrome, that is, hypertriglyceridemia and a low plasma HDL-C concentration. Moreover, the HDL-C levels were lower and those for TG were higher than those of NL controls. Analysis of variance confirmed that the lipid profiles at baseline for the 5 groups, assigned at random on enrollment in the Heart Positive Study, were not significantly different. As reported for the entire Heart Positive study 16 treatment with fenofibrate+D&E (group 3), niacin+D&E (group 4), and the combined therapy of fenofibrate+niacin+D&E (group 5) significantly reduced plasma TG, with median reductions of 35% to 42%. Treatments including niacin with or without fenofibrate increased median HDL-C by 21% to 24%. Treatments including fibrate with or without niacin reduced median non-HDL-C by 20% to 25%.
Altered Lipoprotein Composition in HIV/ART
Compared with NL controls, low-density lipoprotein (LDL)-%TG values of Heart Positive HIV/ART patients at baseline were a median 2-fold higher, whereas other constituents were not significantly different (Table 1) . HDL compositions were also significantly different, with higher %TG, % cholesteryl ester (CE), and % free cholesterol (core components), and lower % phospholipid and % protein (surface components) in Heart Positive HIV/ART patients versus NL controls. The fraction of HDL composed of surface and core components, respectively, were lower and higher in HIV/ART patients with significant elevations of both the %CE and the %TG. The elevation of neutral lipid core components suggested that hypertriglyceridemic HIV/ ART HDL is larger than NL HDL.
Effect of Treatment on Lipoprotein Composition
The 5 treatment arms differentially affected HDL and LDL neutral lipid compositions. As expected, the placebo group showed no change in HDL and LDL composition ( Figure 1 ; group 1). The various treatments did not have much effect on lipoprotein CE content ( Figure 1A and 1C ). Although increased for all treatments, median LDL %CE (average increase of 4%) was not significantly different except for group 2 (D&E). Similarly, although all treatments trended toward decreased HDL %CE (average 6%), this was not significant. In contrast, all 4 interventions reduced the median LDL %TG contents ( Figure 1B ) and HDL %TG ( Figure 1D ). Because of the limited sample size and large individual variability in %TG values, the differences in paired entry versus after-therapy values for any single treatment group only approached P<0.05 significance. However, for all treatments combined there was a 24% decrease in LDL %TG (P=0.003) and a 25% decrease in HDL %TG (P=0.004). These results indicate that whereas the elevated TG contents of both LDL and HDL were responsive to treatment, the elevated CE content of HTG-HIV/ART HDL was more resistant to these treatment protocols.
Hypertriglyceridemic HIV/ART HDL Are not Stable on Freezing
As the neutral core to surface lipid ratio of lipoproteins increases, the particle size increases. 17 Assessment of lipoprotein particle size by size exclusion chromatography (SEC) revealed that Heart Positive HIV/ART HDL were unstable on freezing and exhibited other SEC peaks eluting earlier (larger particle size), which were absent from the chromatograms of normal HDL (Figure 2A ). We assigned these large species to HDL fusion. 18 As shown in Figure 2B , SEC uncovers freezing-dependent differences in the profile of NL control HDL after multiple freeze-thaw cycles. However, the effect of freeze-thaw is much more profound for the HDL from 4 Heart Positive HIV/ ART patients. Thus, the frozen-while-stored samples could not be used for studies of HDL sizing or functionality.
HDL Composition of Non-HTG HIV/ART
HIV/ART HDL from a second HIV/ART patient group were stored at 4°C. The plasma lipid values for HIV/ART 
HIV/ART HDL Are Less Stable to Chaotropic Perturbation Than NL Control HDL
Incubation of HDL with guanidinium chloride (GdmCl) induces the release of lipid-free apolipoprotein (apo)AI and the formation of a larger fused HDL ( Figure 3 ). 18, 19 Comparison of the effects of GdmCl on the lipoprotein profiles of HDL from NL controls and HIV/ART patients revealed notable differences in the amounts of the released products ( Figure 3A and 3B). Although GdmCl converted the HDL from both NL controls and HIV/ART patients to the expected products, the relative amounts of fused HDL and lipid-free apoAI formed were different ( Figure 3C and 3D). Post-GdmCl, the relative amount of HDL remaining was lower and the amount of lipidfree apoAI was higher in HIV/ART HDL versus NL control HDL. Accordingly, even non-HTG HIV/ART HDL is less stable than NL HDL.
HIV/ART Lipoproteins Are Larger Than NL Control Lipoproteins
The high neutral lipid content of LDL and HDL of Heart Positive patients suggested these might be larger lipoproteins. 17 The sizes of lipoproteins in the total lipoproteins (TLP) from non-HTG HIV patients and controls were compared by SEC ( Figure II in the online-only Data Supplement). The means±SE of these data, calculated and plotted as shown in Figure 4 , reveal profound differences between HIV/ART and NL control TLP. NL control TLP contains prominent peaks for VLDL, LDL, and HDL with relatively small SEs ( Figure 4A ). SEC profiles for HIV/ART TLP differ ( Figure 4B ). First, peaks for the 3 major lipoproteins are shifted to earlier elution volumes corresponding to larger particle sizes (compare gray vertical lines). Second ( Figure 4B , ×10 insert), the SEC of HIV/ART TLP contains a peak between LDL and VLDL, which we assign to intermediate density lipoprotein (IDL). Last, the SEs at each elution volume of the HIV/ART TLP chromatogram are much larger than those of control TLP. The relative amounts of the lipoproteins are also altered. On the basis of the ratios of the peak heights, HIV/ART lipoproteins are altered relative to NL controls, with higher amounts of VLDL and IDL relative to LDL and HDL ( Figure 5 ). The ratios relative to LDL for NL controls and HIV/ART patients are as follows: VLDL/LDL=1.10 versus 2.10 (P=0.032); IDL/LDL=0.160 versus 0.436 (P=0.001). These larger sizes, and the greater amounts of VLDL and IDL relative to LDL and HDL, suggest delayed processing of apoB lipoproteins in HIV plasma.
D&E
Validation of a Functional Assessment of NL Control Versus HIV/ART HDL
Because of the altered CE content and the lower stability of the HIV/ART HDL samples, we hypothesized that HIV/ART HDL are dysfunctional in the final step of reverse cholesterol transport, transfer of HDL CE to hepatocytes. The most straightforward method for measuring hepatocyte HDL-CE uptake requires preparation of HDL-[ 3 H]CE, a procedure that can take 10 days and requires significant quantities of starting HDL 20 to yield HDL-[ 3 H]CE with >99% radiochemical purity, 21, 22 followed by uptake assays according to Acton et al. 23 This assay is impractical in the context of large patient numbers and limited plasma volumes, so we modified and validated a competitive assay of hepatic CE uptake that we have used to compare the HDL-[ 3 H]CE uptake before and after remodeling by streptococcal serum-opacity factor. 20 This assay uses NL controls and HIV/ART patient HDL to compete with the uptake of a standard stock HDL-[ 3 H]CE ( Figure III in the online-only Data Supplement). Inhibition constants, ID 50% , were calculated from the inhibitor HDL dose-response curves.
In this assay, a large ID 50% corresponds to HDL that interacts poorly with hepatic HDL receptors and vice versa. Our assay is reproducible; each panel in Figure III in the online-only Data Supplement contains assays on the same HDL sample repeated on different days, with ≤17 weeks between assays. Assays in triplicate showed a within-day variability of 10.6% (n=28) and day-to-day variability of 10.4% (n=4). . Stability was assessed on the basis of the HDL peak height after treatment (C) and the lipid-free apolipoprotein (apo)AI/HDL fused ratio (D). Less fused (lipidated) HDL and more lipid-free apoAI is formed from the HDL of the HIV/ART patients than from that of the NL controls. July 2013
HIV HDL Is a Poor Competitor for Hepatocyte HDL-CE Uptake
Using this competitive inhibition assay, we compared the ID 50% of HDL from HIV/ART patients with those from NL controls. As shown in Figure 6A , ID 50% for individual NL and HIV/ ART HDL distributed over a wide range, 72 to 211 and 75 to 191 µg/mL HDL protein for NL and HIV/ART, respectively. These ranges, which are far greater than the assay variability, illustrate the individual heterogeneity of donor HDL with respect to selective hepatic CE uptake and the power of this assay to distinguish HDL functionality on the basis of hepatic CE uptake. Our data show that the mean ID 50% for the NL group was lower than that of the HIV/ART subjects (ranksum P=0.052), indicating the HIV/ART HDL was a poorer competitor, that is, required more HDL to reach its ID 50% .
Importantly, adjustment of these data for each donor's HDL-C level, which were lower for the HIV/ART patients ( Figure 6B ), revealed the dysfunctionality of HIV/ART HDL. The difference between HIV/ART and NL plasma to affect HDL-CE uptake was profound-CE uptake inhibition by HIV/ART HDL, expressed as plasma volume-equivalents, was much lower. NL plasma contains 23.6±1.7 ID 50% units/ mL versus 14.0±1.8 ID 50% units/mL for HIV/ART plasma (P<0.001). The mean Table 3 . rate of CE uptake from HDL-[ 3 H]CE is inhibited on average twice more effectively by NL HDL than by HIV/ART HDL, when measured at plasma concentrations of the respective HDL. Thus, at plasma concentrations HIV/ART HDL interact with hepatocytes less effectively than NL HDL do.
HDL Composition of Heart Positive HIV, HIV With Isolated Low HDL-C (Non-HTG HIV), and NL Control Donors*
Discussion
Plasma Lipid Profiles of HIV/ART Patients With HTG or Isolated Low HDL-C Versus NL Controls
The Heart Positive HIV/ART patients in the 4 therapeutic and placebo groups have similar lipid profiles ( Table I in the online-only Data Supplement). The higher LDL-and HDL-TG contents within the HTG HIV/ART group (Table 1) are consistent with the CE transfer protein-mediated transfer of TG from VLDL, which are elevated, to LDL and HDL. This effect is dose dependent with respect to fasting plasma TG levels and is expected to yield less stable TG-rich LDL and HDL. 24 TG enrichment may underlie the greater freeze instability of Heart Positive versus control subjects. The effects of the interventions on LDL and HDL compositions were consistent with this model (Figure 1) . LDL-and HDL-TG from patients on D&E and receiving niacin or fenofibrate were lower. The plasma lipoprotein profile of the non-HTG HIV/ART patients was characterized by isolated low HDL-C (Table 2) , low HDL %CE, and a TG-enriched neutral lipid core ( Table 3 ).
Metabolism of HIV/ART Lipoproteins Is Impaired
According to the total lipoprotein (TLP) SEC profiles, the dyslipidemia in HIV/ART patients is highly heterogeneous (large SEs), and is associated with the appearance of lipoproteins that are larger than those of NL controls (Figure 4 ). Consistent with this, the data of Aragonès et al 25 showed greater heterogeneity in HIV HDL and increased CE in the larger HDL subfractions. Two observations suggest that increased lipoprotein heterogeneity is a result of impaired lipoprotein hydrolysis. First, the SEC profiles ( Figure 4 ) showed that all HIV/ART lipoproteins elute earlier than their NL control counterparts; second, these data also show that unlike control TLP, HIV/ART TLP contains a prominent peak for IDL ( Figure 4 ). Increased amounts of VLDL and IDL in HIV/ART fasting plasma indicate delayed processing of these lipoproteins ( Figure 5 ). Given that both IDL-and HDL-TG are substrates for hepatic lipase (HL), which reduces their size by hydrolysis, we hypothesize that HL activity is impaired under the conditions of HIV/ART dyslipidemia, a hypothesis that is supported by reports that HL and to a lesser extent lipoprotein lipase activities are lower in HIV/ART-associated dyslipidemia 26 ; lower lipoprotein lipase activity would also explain the larger HIV/ART versus NL control VLDL. Although endothelial lipase activity has not been reported in HIV samples, low endothelial lipase activity could also cause larger HDL as well as reduced HDL phospholipid, 27 but would be expected to cause higher rather than lower plasma HDL-C. 28
Interaction of HIV/ART HDL With Hepatocytes Is Impaired
According to our competitive assay of HDL-CE uptake by Huh7 cells, differences in the ID 50% of NL control versus HIV/ ART HDL were nearly significant (P=0.052; Figure 6A ). Moreover, when the ID 50% data were normalized to the plasma HDL-C levels of each individual, HIV/ART plasma contained significantly less competitive inhibition activity for hepatocyte HDL-CE uptake than NL plasma did (P<0.001). Decreased interaction of HIV/ART HDL with hepatic receptors may contribute to the observed elevated HDL %CE in the Heart Positive patient population (Table 1 ). It would suggest that the higher HDL-CE may result from an inability of HIV/ART HDL to deliver its CE to hepatocyte receptors for uptake and clearance. The molecular basis for this is not known but may be a result of altered surface protein structure or configuration in response to an altered core composition.
HDL Stability
HIV/ART HDL were found to be less stable than NL HDL both on freezing and on chaotropic perturbation. Importantly, HDL instability has been uncovered by lecithin:cholesterol acyltransferase, CE transfer protein, phospholipid transfer protein, and serum-opacity factor, all of which induce fusion or the release of lipid-free apoAI. 22, [29] [30] [31] [32] Although there have been many studies of the effects of GdmCl on HDL, 18, 19, 33, 34 this study is the first to show that the effects of GdmCl on HDL vary among dyslipidemic patients and NL controls, and that the NL control and HIV/ART HDL respond differently to this denaturant. According to several studies, HDL resides in a kinetic trap from which it can escape via both physico-chemical 18, 19 and biological perturbationslecithin:cholesterol acyltransferase, CE transfer protein, phospholipid transfer protein, and serum-opacity factor. [29] [30] [31] 35 Thus, in the context of the kinetic model of Gursky, 18 HIV/ ART HDL is less stable than NL control HDL. Given that a major marker of instability is the release of lipid-free apoAI, one could speculate that the plasma factors cited above mediate production of more lipid-free apoAI in HIV/ART patients compared with NL controls. A negative consequence of this would be increased renal clearance of apoAI, which would have the effect of lowering plasma HDL-C levels; this hypothesis needs more rigorous testing.
A Metabolic Model of Dysfunctional Lipoprotein Processing in HIV/ART Dyslipidemia
According to our data, HIV/ART dyslipidemia is associated with larger HDL, LDL, and VLDL, and impaired HDL hepatocyte binding, which likely affects hepatocyte HDL-CE uptake. Other studies in HIV patients have demonstrated peripheral tissue hyperlipolytic activity 11 and lower lipoprotein and HL activities. 26, 36 In contrast, the initial step in reverse cholesterol transport, macrophage-cholesterol efflux to HDL, is unaltered by HIV and its treatment. Rose et al 8 found similar rates of activated RAW 264.7 macrophage-cholesterol efflux to plasma of HIV-infected patients, currently treated HIV-infected patients, and HIV-negative subjects. Taken together, these data support a metabolic model for HIV dyslipidemia (Figure 7 ) that begins with peripheral tissue hyperlipolytic activity 11 that results in the release of higher amounts of free fatty acids that are extracted by the liver and used for the production of more VLDL, thereby producing a hypertriglyceridemic state. In the presence of high VLDL-TG concentrations, CE transfer protein mediates the exchange of VLDL TG for HDL and LDL-CE, thereby producing TG-rich HDL and LDL. CE transfer protein activity has been reported to be elevated 8 or within normal limits 37 in HIV/ ART subjects. Lipoprotein-TG hydrolysis by HL reduces their sizes by removing core lipids, and when this process is inhibited larger TG-rich lipoprotein species are observed. In our study, there is even some residual IDL, which under normolipemic conditions is converted to LDL by HL. All lipoprotein classes from HIV/ART are larger than those from NL subjects suggesting resistance to the activities of hepatic or lipoprotein lipases. As a consequence of the high TG content of the HDL particles, we speculate that they are less stable and that the HIV/ART apoAI is more labile than that of NL HDL. Whether the instability influences function remains to be investigated. Nevertheless, the CE of HIV/ART HDL are hepatically extracted at a lower rate than those of NL HDL because of their intrinsically lower uptake and the lower plasma HDL-C levels in HIV/ART patients. 
